Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SABS

SABS - SAB Biotherapeutics, Inc. Stock Price, Fair Value and News

3.22USD-0.08 (-2.42%)Market Closed

Market Summary

SABS
USD3.22-0.08
Market Closed
-2.42%

SABS Stock Price

View Fullscreen

SABS RSI Chart

SABS Valuation

Market Cap

30.5M

Price/Earnings (Trailing)

-0.76

Price/Sales (Trailing)

11.7

EV/EBITDA

-0.47

Price/Free Cashflow

-0.88

SABS Price/Sales (Trailing)

SABS Profitability

EBT Margin

-1531.84%

Return on Equity

-75.47%

Return on Assets

-55.86%

Free Cashflow Yield

-113.5%

SABS Fundamentals

SABS Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

62.55%

Rev. Growth (Qtr)

209.69%

SABS Earnings

Earnings (TTM)

-39.9M

Earnings Growth (Yr)

31.66%

Earnings Growth (Qtr)

78.01%

Breaking Down SABS Revenue

52 Week Range

3.43
(Low)(High)

Last 7 days

20.9%

Last 30 days

-19.3%

Last 90 days

-45%

How does SABS drawdown profile look like?

SABS Financial Health

Current Ratio

5.65

Debt/Equity

0.01

Debt/Cashflow

-63.26

SABS Investor Care

Buy Backs (1Y)

81.69%

Diluted EPS (TTM)

-9.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.6M000
202312.7M6.4M4.1M2.2M
202255.8M43.9M32.8M23.9M
202156.6M58.1M59.5M60.9M
20200029.3M55.2M
20190003.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of SAB Biotherapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 07, 2023
sullivan eddie joe
bought
1,531
0.88
1,740
chief executive officer
Nov 30, 2023
king michael
bought
4,500
0.9
5,000
chief financial officer
Nov 29, 2023
reich samuel j
bought
9,841
0.8947
11,000
executive chairman
Nov 24, 2023
ellias helen k.
acquired
-
-
2,857,140
-
Nov 24, 2023
moin andrew
acquired
-
-
4,584,570
-
Nov 24, 2023
sessa capital (master), l.p.
acquired
-
-
4,584,570
-
Mar 14, 2023
kropotova alexandra
acquired
-
-
275,000
chief medical officer
Dec 07, 2022
hamilton christine e
acquired
99,999
1.205
82,987
-
Dec 07, 2022
link david charles
acquired
49,999
1.205
41,493
-
Dec 07, 2022
spragens jeffrey g
acquired
99,999
1.205
82,987
-

1–10 of 43

Which funds bought or sold SABS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Shaolin Capital Management LLC
reduced
-21.17
202
11,426
-%
May 15, 2024
Kestra Advisory Services, LLC
sold off
-100
-60,500
-
-%
May 15, 2024
RTW INVESTMENTS, LP
new
-
4,166,930
4,166,930
0.06%
May 15, 2024
RTW INVESTMENTS, LP
sold off
-100
-6,310,070
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
6,519
6,519
-%
May 15, 2024
Tower Research Capital LLC (TRC)
unchanged
-
1.00
2.00
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-10,482
-
-%
May 15, 2024
LMR Partners LLP
unchanged
-
4,748
21,044
-%
May 15, 2024
Sessa Capital IM, L.P.
new
-
2,081,400
2,081,400
0.05%
May 15, 2024
Sessa Capital IM, L.P.
sold off
-100
-3,151,890
-
-%

1–10 of 49

Are Funds Buying or Selling SABS?

Are funds buying SABS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SABS
No. of Funds

Unveiling SAB Biotherapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
radcliffe capital management, l.p.
0.00%
0
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.99%
9,220,672
SC 13G
Feb 14, 2024
commodore capital lp
3.5%
1,831,746
SC 13G/A
Dec 04, 2023
biotechnology value fund l p
5.3%
4,896,104
SC 13G
Oct 16, 2023
commodore capital lp
9.9%
6,932,463
SC 13G

Recent SEC filings of SAB Biotherapeutics, Inc.

View All Filings
Date Filed Form Type Document
May 31, 2024
8-K
Current Report
May 30, 2024
DEF 14A
DEF 14A
May 21, 2024
8-K
Current Report
May 20, 2024
10-Q
Quarterly Report
May 15, 2024
NT 10-Q
NT 10-Q
May 14, 2024
3
Insider Trading
May 08, 2024
8-K
Current Report
Apr 15, 2024
8-K
Current Report
Mar 29, 2024
8-K
Current Report
Mar 29, 2024
10-K
Annual Report

Peers (Alternatives to SAB Biotherapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

SAB Biotherapeutics, Inc. News

Latest updates
Defense World08 Jun 202407:00 am
InvestorPlace21 May 202407:00 am

SAB Biotherapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Revenue209.7%944,575305,0111,267,36185,518581,1012,160,8723,589,7086,350,52511,803,07711,058,25314,680,58918,209,50216,927,734---
Operating Expenses-35.7%12,335,19119,178,7826,590,2836,562,1367,983,11010,020,88511,397,02412,893,46918,510,41618,402,48518,670,94321,082,04316,113,8108,996--
  S&GA Expenses-71.8%4,189,12114,881,3462,570,5652,900,0063,447,3892,863,4494,044,0464,309,0425,186,0727,754,5673,600,6782,398,6413,331,806---
  R&D Expenses89.6%8,146,0704,297,4364,019,7183,662,1304,535,7217,157,4367,352,9788,584,42713,324,34410,647,91815,070,26518,683,40212,782,004---
EBITDA Margin21.6%-13.37-17.05-5.67-3.94-1.84-0.64-0.59-0.38-0.27-0.250.350.360.370.38--
Interest Expenses-1.9%76,37177,87969,70075,32092,38587,69970,62671,23772,02266,27578,55874,43475,192---
Income Taxes---------92,28192,281-------
Earnings Before Taxes78.0%-5,025,745-22,856,763-5,102,317-6,880,886-7,353,820-7,848,970-7,076,068-4,868,2771,078,144-11,551,496-4,061,190-2,941,6791,409,834---
EBT Margin18.7%-15.32-18.84-6.64-4.54-2.14-0.78-0.68-0.44-0.31-0.280.340.350.360.36--
Net Income78.0%-5,025,745-22,856,763-5,102,317-6,880,886-7,353,820-7,874,599-7,076,068-4,775,996985,863-11,551,496-4,061,190-2,941,6791,409,834-8,996--
Net Income Margin18.7%-15.32-18.84-6.65-4.55-2.14-0.78-0.68-0.44-0.32-0.28-0.090.350.360.36--
Free Cashflow19.5%-10,879,083-13,514,581-5,253,121-4,921,840-1,627,017-1,672,778-7,997,224-5,060,874-10,895,049-7,240,091569,315-9,849,3477,563,339---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-15.0%71.0084.0028.0035.0043.0051.0053.0059.0068.0081.0051.0011711757.0018.00
  Current Assets-20.3%47.0059.003.009.0015.0022.0022.0028.0037.0050.0022.001.001.0034.009.00
    Cash Equivalents-75.2%14.0057.002.008.0013.0015.008.0017.0022.0033.0011.0010.0020.0013.006.00
  Net PPE-9.3%18.0020.0021.0022.0022.0023.0024.0025.0025.0024.0023.00--15.003.00
Liabilities-30.4%19.0027.0013.0016.0018.0020.0022.0022.0027.0043.0016.0010.008.0018.0010.00
  Current Liabilities-23.2%8.0011.009.0011.0014.0015.0017.0016.0019.0026.0010.000.000.0011.005.00
  Long Term Debt----1.001.001.00---------
    LT Debt, Non Current----1.001.001.00---------
Shareholder's Equity-7.8%53.0057.0015.0020.0024.0031.0031.0037.0041.0039.0035.0038.0041.0039.008.00
  Retained Earnings-5.6%-95.09-90.06-67.21-62.10-55.20-47.87-40.00-32.92-28.14-29.13-17.58-8.96-6.76-11.98-32.10
  Additional Paid-In Capital0.4%15315388.0087.0085.0084.0076.0076.0075.0068.0053.00-4.24-2.0451.0030.00
Shares Outstanding0.0%9.009.009.0052.005.005.0043.0043.0043.0043.0026.0026.0026.0026.00-
Float----31.00---33.00---115---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations20.1%-10,750-13,446-5,167-4,899-1,605-1,555-7,918-4,448-9,537-4,8783,797-6,3859,453-10.03--
  Share Based Compensation15.0%617537639645603629578570898651881433349---
Cashflow From Investing-46108.9%-31,359-67.86-40.86-22.68-21.30-117-78.50-612-1,280-2,361-3,228-3,463-1,890---
Cashflow From Financing-100.6%-39467,637-140-363-3598,387-287-731-6,31736,034-51.23-46.23-45.4795.00--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SABS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue  
Total revenue$ 944,575$ 581,101
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Grant Revenue [Member]Grant Revenue [Member]
Operating Expenses [Abstract]  
Research and Development Expense$ 8,146,070$ 4,535,721
General and Administrative Expense4,189,1213,447,389
Total operating expenses12,335,1917,983,110
Loss from operations(11,390,616)(7,402,009)
Changes in fair value of warrant liabilities5,468,21982,586
Interest expense(76,371)(92,385)
Interest income497,89357,988
Other income475,130 
Total other income (expense)6,364,87148,189
Loss before income taxes(5,025,745)(7,353,820)
Net loss(5,025,745)(7,353,820)
Other comprehensive loss:  
Unrealized gain (loss), change in fair value of available-for-sale securities, net of tax(56,061) 
Foreign currency translation(33,807) 
Total comprehensive loss$ (5,115,613)$ (7,353,820)
Loss per common share attributable to the Company's shareholders  
Basic loss per common share$ (0.54)$ (1.46)
Diluted loss per common share$ (0.54)$ (1.46)
Weighted-average common shares outstanding - basic9,241,9405,039,705
Weighted-average common shares outstanding - diluted9,241,9405,039,705

SABS Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 14,034,162$ 56,566,066
Short-term investments30,022,9160
Accrued interest receivable193,2320
Prepaid expenses and other current assets2,701,0402,340,797
Total current assets46,951,35058,906,863
Deferred issuance cost236,1050
Long-term prepaid insurance317,922350,230
Long-term investments1,235,1500
Operating lease right-of-use assets1,080,0491,277,982
Financing lease right-of-use assets3,647,9533,669,659
Property, plant and equipment, net17,902,55319,736,519
Total assets71,371,08283,941,253
Current liabilities  
Accounts payable1,239,943945,927
Notes payable835,4671,050,849
Operating lease liabilities, current portion542,841669,946
Finance lease liabilities, current portion134,568132,004
Deferred grant income377,8351,322,410
Accrued expenses and other current liabilities5,174,3166,692,181
Total current liabilities8,304,97010,813,317
Operating lease liabilities, noncurrent554,547635,777
Finance lease liabilities, noncurrent3,383,8643,418,483
Warrant liabilities6,306,01611,774,235
Total liabilities18,549,39726,641,812
Commitments and contingencies (Note 18)
Stockholders equity  
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 42,236 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively55
Common stock; $0.0001 par value; 800,000,000 shares authorized at March 31,2024 and December 31, 2023; 9,283,939 and 9,280,159 shares issued, respectively, and 9,229,274 and 9,225,494 outstanding at March 31,2024 and December 31, 2023, respectively929929
Treasury stock, at cost; 54,665 shares held at March 31, 2024 and December 31, 2023(5,521,246)(5,521,246)
Additional paid-in capital153,494,731152,856,874
Accumulated other comprehensive income (loss)(63,448)26,420
Accumulated deficit(95,089,286)(90,063,541)
Total stockholders' equity52,821,68557,299,441
Total liabilities and stockholders equity$ 71,371,082$ 83,941,253
SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
 CEO
 WEBSITEsabbiotherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES56

SAB Biotherapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for SAB Biotherapeutics, Inc.? What does SABS stand for in stocks?

SABS is the stock ticker symbol of SAB Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SAB Biotherapeutics, Inc. (SABS)?

As of Wed Jun 12 2024, market cap of SAB Biotherapeutics, Inc. is 30.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SABS stock?

You can check SABS's fair value in chart for subscribers.

What is the fair value of SABS stock?

You can check SABS's fair value in chart for subscribers. The fair value of SAB Biotherapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SAB Biotherapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SABS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SAB Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SABS is over valued or under valued. Whether SAB Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact SAB Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SABS.

What is SAB Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, SABS's PE ratio (Price to Earnings) is -0.76 and Price to Sales (PS) ratio is 11.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SABS PE ratio will change depending on the future growth rate expectations of investors.